AIM ImmunoTech Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are bearish, financial performance is deteriorating, and there are no positive catalysts or significant trading trends to support a buy decision.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 39.382, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.841 and 0.697, while resistance levels are at 1.307 and 1.451. The stock closed at $1, below its pivot of 1.074, indicating weakness.

Positive Catalysts

NULL. There is no recent news, no significant trading trends, and no positive signals from Intellectia Proprietary Trading Signals.

Neutral/Negative Catalysts

The company reported a significant decline in financial performance in Q3 2025, with revenue down 25.71% YoY, net income down 11.24% YoY, EPS down 75.51% YoY, and gross margin deteriorating by 309.41%. Additionally, there are no recent insider or hedge fund buying trends, and the stock is in a bearish technical setup.

Financial Performance

In Q3 2025, AIM ImmunoTech reported a revenue drop to $26,000 (-25.71% YoY), net income fell to -$3,284,000 (-11.24% YoY), EPS dropped to -1.57 (-75.51% YoY), and gross margin plummeted to -161.54% (-309.41% YoY). The financials indicate a significant decline in performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast AIM stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.908

Low

Averages

High